NASDAQ:PRCT PROCEPT BioRobotics (PRCT) Stock Price, News & Analysis → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free PRCT Stock Alerts $62.79 +1.36 (+2.21%) (As of 05/7/2024 ET) Add Compare Share Share Today's Range$61.04▼$63.0750-Day Range$45.73▼$64.3152-Week Range$24.83▼$65.00Volume679,194 shsAverage Volume545,750 shsMarket Capitalization$3.23 billionP/E RatioN/ADividend YieldN/APrice Target$61.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get PROCEPT BioRobotics alerts: Email Address PROCEPT BioRobotics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside2.5% Downside$61.20 Price TargetShort InterestBearish11.04% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.45Based on 42 Articles This WeekInsider TradingSelling Shares$7.77 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.96) to ($1.48) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.50 out of 5 starsMedical Sector844th out of 903 stocksSurgical & Medical Instruments Industry90th out of 95 stocks 1.5 Analyst's Opinion Consensus RatingPROCEPT BioRobotics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePROCEPT BioRobotics has only been the subject of 3 research reports in the past 90 days.Read more about PROCEPT BioRobotics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted11.04% of the float of PROCEPT BioRobotics has been sold short.Short Interest Ratio / Days to CoverPROCEPT BioRobotics has a short interest ratio ("days to cover") of 11.3, which indicates bearish sentiment.Change versus previous monthShort interest in PROCEPT BioRobotics has recently increased by 15.27%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPROCEPT BioRobotics does not currently pay a dividend.Dividend GrowthPROCEPT BioRobotics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRCT. Previous Next 3.0 News and Social Media Coverage News SentimentPROCEPT BioRobotics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 42 news articles for PROCEPT BioRobotics this week, compared to 4 articles on an average week.Search Interest1 people have searched for PRCT on MarketBeat in the last 30 days. MarketBeat Follows2 people have added PROCEPT BioRobotics to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PROCEPT BioRobotics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,770,023.00 in company stock.Percentage Held by Insiders19.60% of the stock of PROCEPT BioRobotics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.46% of the stock of PROCEPT BioRobotics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about PROCEPT BioRobotics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for PROCEPT BioRobotics are expected to grow in the coming year, from ($1.96) to ($1.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PROCEPT BioRobotics is -29.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PROCEPT BioRobotics is -29.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPROCEPT BioRobotics has a P/B Ratio of 11.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about PROCEPT BioRobotics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report About PROCEPT BioRobotics Stock (NASDAQ:PRCT)PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.Read More PRCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRCT Stock News HeadlinesMay 7, 2024 | insidertrades.comThomas M. Krummel Sells 20,000 Shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT) StockMay 4, 2024 | insidertrades.comInsider Selling: PROCEPT BioRobotics Co. (NASDAQ:PRCT) EVP Sells 30,432 Shares of StockMay 7, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.May 7, 2024 | americanbankingnews.comPROCEPT BioRobotics Co. (NASDAQ:PRCT) Director Thomas M. Krummel Sells 20,000 SharesMay 7, 2024 | americanbankingnews.comPROCEPT BioRobotics (NASDAQ:PRCT) Trading Down 4.3% After Insider SellingMay 6, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Fulgent Genetics (FLGT), Cigna (CI) and PROCEPT BioRobotics (PRCT)May 6, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and PROCEPT BioRobotics (PRCT)May 6, 2024 | markets.businessinsider.comUnveiling 4 Analyst Insights On PROCEPT BioRoboticsMay 7, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.May 6, 2024 | globenewswire.comReal-World, Long-Term Data Demonstrate Sustained Benefits of Aquablation Therapy for Men with Benign Prostatic HyperplasiaMay 6, 2024 | americanbankingnews.comBrokers Set Expectations for PROCEPT BioRobotics Co.'s Q2 2024 Earnings (NASDAQ:PRCT)May 5, 2024 | americanbankingnews.comAlaleh Nouri Sells 30,432 Shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT) StockMay 4, 2024 | finance.yahoo.comPROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported And Analysts Have Been Lifting Their Price TargetsMay 4, 2024 | americanbankingnews.comQ2 2024 Earnings Forecast for PROCEPT BioRobotics Co. Issued By William Blair (NASDAQ:PRCT)May 3, 2024 | finance.yahoo.comPROCEPT BioRobotics First Quarter 2024 Earnings: Beats ExpectationsMay 3, 2024 | finance.yahoo.comPROCEPT BioRobotics Corporation (NASDAQ:PRCT) Q1 2024 Earnings Call TranscriptMay 3, 2024 | americanbankingnews.comPROCEPT BioRobotics (NASDAQ:PRCT) Reaches New 52-Week High After Better-Than-Expected EarningsMay 2, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT), Cross Country Healthcare (CCRN) and CVS Health (CVS)May 2, 2024 | finance.yahoo.comPROCEPT BioRobotics Corp (PRCT) Q1 2024 Earnings Call Transcript Highlights: Soaring Revenues ...May 1, 2024 | markets.businessinsider.comBuy Rating Affirmed on PROCEPT BioRobotics’ Strong Performance and Promising Growth TrajectoryMay 1, 2024 | investorplace.comPRCT Stock Earnings: PROCEPT BioRobotics Beats EPS, Beats Revenue for Q1 2024May 1, 2024 | finance.yahoo.comBiotech Leader Procept BioRobotics Jumps Past Buy Point On EarningsMay 1, 2024 | globenewswire.comPROCEPT BioRobotics Reports First Quarter 2024 Financial Results and Increases 2024 Revenue GuidanceMay 1, 2024 | americanbankingnews.comPROCEPT BioRobotics (NASDAQ:PRCT) and Autonomix Medical (NASDAQ:AMIX) Critical ReviewApril 30, 2024 | markets.businessinsider.comHere's what Wall Street expects from PROCEPT BioRobotics's earningsApril 29, 2024 | finance.yahoo.comLate Breaking Abstract Presented at the Japanese Urological Association Annual Meeting on Aquablation Therapy Outcomes for Men in Japan with Lower Urinary Tract Symptoms due to Benign Prostatic HyperplasiaApril 27, 2024 | americanbankingnews.comPROCEPT BioRobotics Co. (NASDAQ:PRCT) Receives Average Rating of "Buy" from AnalystsSee More Headlines Receive PRCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PROCEPT BioRobotics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today5/07/2024Next Earnings (Estimated)7/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:PRCT CUSIPN/A CIK1588978 Webwww.procept-biorobotics.com Phone650-232-7200FaxN/AEmployees626Year FoundedN/APrice Target and Rating Average Stock Price Target$61.20 High Stock Price Target$75.00 Low Stock Price Target$37.00 Potential Upside/Downside-2.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-105,900,000.00 Net Margins-66.12% Pretax Margin-66.12% Return on Equity-41.35% Return on Assets-27.92% Debt Debt-to-Equity Ratio0.19 Current Ratio8.52 Quick Ratio7.44 Sales & Book Value Annual Sales$136.19 million Price / Sales23.71 Cash FlowN/A Price / Cash FlowN/A Book Value$5.56 per share Price / Book11.29Miscellaneous Outstanding Shares51,420,000Free Float41,345,000Market Cap$3.23 billion OptionableOptionable Beta0.95 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Reza Zadno Ph.D. (Age 69)President, CEO & Director Comp: $1.13MMr. Kevin Waters (Age 47)Executive VP & CFO Comp: $680.11kMs. Alaleh Nouri (Age 45)EVP, Chief Legal Officer & Corporate Secretary Comp: $605.84kMr. Hisham Shiblaq (Age 48)Executive VP & Chief Commercial Officer Comp: $645.95kMr. Mohan F. Sancheti (Age 60)Senior Vice President of Operations Mr. Barry TemplinExecutive VP of Technology & Clinical DevelopmentMr. Matthew James Bacso C.F.A.Vice President of Investor RelationsMs. Stacey L. Porter (Age 48)Chief People Officer Mr. Bijesh ChandranSenior Vice President of Regulatory Affairs & Quality AssuranceMore ExecutivesKey CompetitorsICU MedicalNASDAQ:ICUITandem Diabetes CareNASDAQ:TNDMIntegra LifeSciencesNASDAQ:IARTInari MedicalNASDAQ:NARIAxonicsNASDAQ:AXNXView All CompetitorsInsiders & InstitutionsLisanti Capital Growth LLCSold 21,035 shares on 5/7/2024Ownership: 0.196%Swiss National BankBought 1,600 shares on 5/7/2024Ownership: 0.174%Sei Investments Co.Bought 6,011 shares on 5/7/2024Ownership: 0.044%SG Americas Securities LLCSold 2,106 shares on 5/7/2024Ownership: 0.019%Quantbot Technologies LPBought 18,437 shares on 5/6/2024Ownership: 0.059%View All Insider TransactionsView All Institutional Transactions PRCT Stock Analysis - Frequently Asked Questions Should I buy or sell PROCEPT BioRobotics stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PROCEPT BioRobotics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PRCT shares. View PRCT analyst ratings or view top-rated stocks. What is PROCEPT BioRobotics' stock price target for 2024? 7 brokerages have issued 1 year target prices for PROCEPT BioRobotics' shares. Their PRCT share price targets range from $37.00 to $75.00. On average, they expect the company's stock price to reach $61.20 in the next year. This suggests that the stock has a possible downside of 2.5%. View analysts price targets for PRCT or view top-rated stocks among Wall Street analysts. How have PRCT shares performed in 2024? PROCEPT BioRobotics' stock was trading at $41.91 at the start of the year. Since then, PRCT shares have increased by 49.8% and is now trading at $62.79. View the best growth stocks for 2024 here. When is PROCEPT BioRobotics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 25th 2024. View our PRCT earnings forecast. How were PROCEPT BioRobotics' earnings last quarter? PROCEPT BioRobotics Co. (NASDAQ:PRCT) announced its earnings results on Wednesday, May, 1st. The company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.04. The company earned $44.50 million during the quarter, compared to analysts' expectations of $41.58 million. PROCEPT BioRobotics had a negative trailing twelve-month return on equity of 41.35% and a negative net margin of 66.12%. The business's quarterly revenue was up 82.4% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.63) earnings per share. What ETFs hold PROCEPT BioRobotics' stock? ETFs with the largest weight of PROCEPT BioRobotics (NASDAQ:PRCT) stock in their portfolio include Innovator IBD Breakout Opportunities ETF (BOUT), Innovator IBD 50 ETF (FFTY), SPDR S&P Health Care Equipment ETF (XHE), Global X Robotics & Artificial Intelligence Thematic ETF (BOTZ), ALPS Disruptive Technologies ETF (DTEC), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), First Trust Small Cap Growth AlphaDEX Fund (FYC) and Principal Healthcare Innovators ETF (BTEC). What guidance has PROCEPT BioRobotics issued on next quarter's earnings? PROCEPT BioRobotics updated its FY 2024 earnings guidance on Wednesday, May, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $213.5 million-$213.5 million, compared to the consensus revenue estimate of $210.2 million. When did PROCEPT BioRobotics IPO? PROCEPT BioRobotics (PRCT) raised $126 million in an initial public offering on Wednesday, September 15th 2021. The company issued 5,500,000 shares at $22.00-$24.00 per share. Who are PROCEPT BioRobotics' major shareholders? PROCEPT BioRobotics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Mirae Asset Global Investments Co. Ltd. (0.77%), Allspring Global Investments Holdings LLC (0.39%), Lisanti Capital Growth LLC (0.20%), Swiss National Bank (0.17%), Taylor Frigon Capital Management LLC (0.16%) and Essex Investment Management Co. LLC (0.12%). Insiders that own company stock include Alaleh Nouri, Frederic H Moll, Global Investors Lp Viking, Hisham Shiblaq, Kevin Waters, Morgan Colby Wood, Reza Zadno and Thomas M Krummel. View institutional ownership trends. How do I buy shares of PROCEPT BioRobotics? Shares of PRCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PRCT) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorBiden replacement revealed?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldElon Musk Secret Crypto Plot ExposedCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsObama’s Forever Term [exposed]Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PROCEPT BioRobotics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
